NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, announced today that it has submitted a Supplemental Biologics License Application, or sBLA, to the U.S. Food and Drug Administration (FDA) for approval to market Evicel, the Company’s second generation liquid fibrin sealant, with an expanded indication of General Hemostasis in surgery.
